Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular Profiling of Advanced Soft-Tissue Sarcomas
2017-002851-27Phase 3Active
- Sponsor
- Inserm
- Start
- Sep 2018
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of capmatinib, olaparib, durvalumab, glasdegib, futibatinib and 6 more in soft tissue sarcoma (STS) and cancer (2 arms), sponsored by Inserm. Primary endpoint: Feasibility of NGS exome analysis. Started Sep 2018; status: active.
02
Drugs
capmatinibolaparibdurvalumabglasdegibfutibatinib
03
Conditions
soft tissue sarcoma (STS)cancer
Beyond the preview
Go deeper on 2017-002851-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002851-27.